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24% wanted HCPs to talk about factors besides HbA1c. Further, while 44% of HCPs 
interviewed said the easiest way to achieve control was intensifying medication, 
patient’s often associated intensification and/or complex medication regimens as 
a negative aspect of control. CONCLUSIONS: The concept of “being in control” has 
multiple meanings to patients and these definitions are often at odds with HCP 
definitions. This discordance may result in suboptimal patient-HCP interactions 
as well as contribute to physician inertia to initiate and/or intensify treatments. 
Patient education and research is needed to better understand the management 
of uncontrolled diabetes.
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OBJECTIVES: Although literature on EQ-5D in T2DM indicates sensitivity to long-
term complications of the disease, Phase 3 trials, which by necessity are of short 
duration, have failed to detect changes in EQ-5D. The objective of this study was to 
examine if the traditional mean difference approach obscured meaningful changes 
in EQ-5D in a clinical trial of canagliflozin versus glimepiride in dual therapy with 
metformin. METHODS: Mean change in EQ-5D was calculated from baseline to 
Week 52. The empirical distribution of individual change scores was examined to 
assess how well the mean reflected individual experience. Comparisons of clinical 
and patient-reported outcomes (PROs) were performed across subgroups based 
on EQ-5D change (improve, decline, no change) to explore potential correlates of 
response. RESULTS: Mean change in EQ-5D among patients with both data points 
(N = 1,070) was 0.01 with a standard deviation of 0.2, indicating no difference from 
zero. The empirical distribution revealed that only 43.6% of patients had no change, 
while 33.4% improved and 23.0% declined. Decliners were more likely to be female 
(51.6% vs 40.5%), have a history of depression (9.3% vs 5.7%), lower baseline A1C (7.6% 
vs 7.8%), and worse baseline PROs versus those with no change. They also had more 
symptomatic hypoglycemic episodes (20.5% vs 13.7%) and poorer PRO responses. 
Improvers were more likely to be female (50.7% vs 40.5%) and to have worse PROs 
at baseline versus those with no change. They were also more likely to avoid weight 
gain (75.4% vs 69.2%) and symptomatic hypoglycemic episodes (84.5% vs 66.7%), as 
well as report greater improvements in PROs. CONCLUSIONS: This analysis sug-
gests that the mean change in EQ-5D may not sufficiently reflect patient experience 
in clinical trials of T2DM, and that patient-relevant factors such as weight change 
and symptomatic hypoglycemia are likely to be important predictors of response.
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OBJECTIVES: Medication adherence in patients with metabolic syndrome is vital 
for disease control. It is important to recognize patients’ barriers of adherence to 
improve outcomes. The objective of the study is to assess how patient self-reported 
barriers to adherence affect the pill counts of their medications and patient adher-
ence. METHODS: Appointments were held with 30 adult, English speaking patients, 
having type II diabetes, hypertension, hyperlipidemia, at least one oral medication 
for each disease state, and a minimum of five oral prescription medications. Pill 
counts were conducted, and patients were verbally asked seven questions targeting 
adherence barriers with responses assessed using a 4-point Likert-type scale from 
(1) Disagree completely to (4) Agree completely. Some questions included, “In the 
past two weeks, I forgot to take my medication at least once,” “I believe medicines do 
more harm than good.” Patients were placed into seven groups based on responses. 
Patients reporting more than one barrier were placed in multiple groups and pill 
counts of each group were averaged. Groups were analyzed to determine how barri-
ers influence pill count scores. Groups with pill count scores > .80 were determined 
to be adherent. RESULTS: The barrier, “forgot to take my medication,” was the most 
acknowledged of all barriers (N= 12) with a pill count score of .59, conversely (N= 18), 
.52. The least acknowledged barrier “I stop my medication if I do not feel it working” 
(N= 1) had a score of .94, conversely (N= 28), .52. Eight patients did not acknowledge 
any barriers with a pill count score of .44. CONCLUSIONS: Patients’ scores reflected 
that although patients did not report experiencing a barrier, they were non-adherent 
to their medications. Patients may misreport barriers, or not realize the barriers 
affecting them. Healthcare professionals must improve communication targeting 
adherence barriers specific to the patient to improve health outcomes.
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OBJECTIVES: Children with Growth Hormone Deficiency (GHD) can experience 
physical symptoms and limitations as well as a range of social and emotional prob-
lems. Unfortunately, no GHD specific measures exist to assess these impacts. This 
qualitative study identified key symptoms/impacts of GHD disease and treatment 
in order to support the development of a patient-reported outcome measure (PRO) 
for children ages 10-13 and an observer-reported outcome measure (ObsRO) for 
parents/guardians of younger children. METHODS: Focus groups and interviews 
were conducted with 39 children (age 8 -12) with GHD and 34 parents of children (age 
4 to 12) in 3 countries (Germany, UK US). All interviews were transcribed, analyzed, 
and coded thematically using adapted grounded theory to determine overarching 
themes and concepts. Based on the analysis, expert interviews and literature review, 
a conceptual model of GHD impacts was developed. RESULTS: Qualitative analy-
sis found saturation of concepts was reached with 3 domains of impact: Physical, 
Social, and Emotional. Sub-concepts included strength/endurance (48%), appetite 
age, sex, ethnicity, and smartphone ownership. Approximately 67% of patients 
had a computer at home. More than 65% reported interest in using electronic 
methods to interact more with their physician between visits to help manage 
and treat their disease. Patients reported that they were more likely to speak 
with their physician (46%), report disease symptoms (38%), report on their quality 
of life (37%), and take medication (32%) if they had more knowledge about their 
disease. When asked about the most effective way of improving their health and 
managing their disease, 32% responded “increasing communication and interac-
tions between my physician and me”; another 31% were interested in monitoring 
their disease, symptoms, and/or medications electronically so that their physician 
could see their health status in real time. Patients preferred electronic methods of 
managing their disease, including email and text message communications with 
their healthcare provider (73%), clinical visit scheduling via smartphone (76%), 
and medication reminders via smartphone (83%). CONCLUSIONS: Patients are 
interested in using electronic methods to increase communication with their phy-
sician and manage their disease. Possible opportunities for addressing this need 
include educational smartphone apps, medication reminders via text messaging, 
and clinic visit scheduling via smartphone. Providers should consider engaging 
patients with e-clinical technology to increase patient-physician communication 
and for the ultimate goal of improved healthcare.
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OBJECTIVES: To assess the preferences of Spanish and Portuguese patients and 
physicians regarding T2DM treatments and the monthly willingness to pay (WTP) 
for gaining benefits or avoiding side effects. METHODS: An observational, multi-
center, exploratory study focused on routine clinical practice in Spain and Portugal. 
Professionals were recruited from diverse hospitals and outpatient’s clinics while 
patients were recruited from 11 centers operating in the public healthcare system 
in different autonomous communities in Spain and in Portugal. Preferences were 
measured via a discrete choice experiment. Data was analyzed using a conditional 
logit model. RESULTS: 221 professionals from the Spanish and Portuguese NHS [62% 
female; mean age 41.9 (SD: 10.5); 33.5% endocrinologists, 66.5% GP] and 330 patients 
[49.7% female; mean age 62.4 (10.1), mean disease duration 13.98 (8.22) years, mean 
BMI 32.50 (6.82), 41.8% received oral + injected medication, 40.3% received oral and 
17.6% injected treatments] participated. Professionals placed the most value on 
avoiding one hypoglycemia per week [WTP: 287.18€ (95% CI: 160.31 - 1,387.21)], 
followed by avoid gaining 3 Kg/6 months and decreasing cardiovascular risk [WTP: 
166.87€ (88.63 - 843.09) and 154.30€ (98.13 - 434.19), respectively]. Patients placed 
the most value on the weight attribute [WTP: 68.14€ (54.55 - 85.08) to avoid gaining 
3 kg/6 months], followed by avoiding one hypoglycemic event per month [WTP: 
54.80€ (23.29 - 82.26)]. Professionals and patients were willing to pay 125.92€ (73.30 
– 622.75) and 24.28€ (18.41 – 30.31), respectively, to avoid increasing 1% of HbA1c 
and 143.30€ (73.39 – 543.62) and 42.74€ (23.89 – 61.77), respectively, for avoiding 
nausea. CONCLUSIONS: Both patients and professionals in Spain and Portugal are 
willing to pay for the health benefits associated with improved diabetes treatment, 
being the most important avoiding hypoglycemia and gaining weight. Decrease in 
cardiovascular risk and weight reduction became the third most valued attributes 
for professionals and patients, respectively.
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OBJECTIVES: This qualitative study was conducted to address critical gaps on 
how type-2 diabetes patients using basal insulin understand the concept of their 
diabetes “being in control”. METHODS: Forty-nine type-2 diabetes patients on 
basal insulin (focus groups N= 45, individually N= 4) and 9 health care provid-
ers (HCPs), were interviewed in Sweden, Denmark, UK, and Switzerland. Patients 
were asked about their understanding of control, obstacles to achieving and how 
their understanding of control compared with their HCP. The interviews were 
transcribed, coded and qualitatively analyzed, based on grounded theory, to iden-
tify and quantify emerging themes. RESULTS: The mean age of patients was 64 
(range 28-83) with approximately 50% considering their diabetes out of control. 
In contrast to the accepted medical definition of control based on HbA1c (average 
plasma glucose value), 58% of patients associated diabetes control with factors 
other than HbA1c; 80% associated control with daily or hourly meter readings; 76% 
day-to-day feelings; 40% sugar fluctuations, and 38% with limitations in daily life. 
Major obstacles to control were: managing diet/appetite: 87%; inadequate educa-
tion from HCPs: 71%; lack of social support and schedule and lifestyle issues: 69%. 
Only 42% of patients mentioned medication regimen as affecting control. Twenty-
seven percent felt they had different definitions of control than their HCPs, and 
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tal and physical component summary (MCS, PCS) and SF-6D (health utility) scores), 
productivity loss (Work Productivity and Activity Impairment questionnaire) and 
healthcare utilization in the past 6 months. Multivariable analyses were performed 
to adjust for baseline differences (e.g., age, gender, ethnicity, household income, 
insurance status, comorbidity burden, etc.). RESULTS: Among respondents with 
T2DM (n= 7,066; 39.5% female; 60.0 years), 63.0% were obese, 23.0% had SD, and 17.4% 
had obesity and SD. Multivariable analyses showed significantly worsening health 
status and greater productivity loss and healthcare utilization among respondents 
with T2DM who also had obesity or SD, or both. Respondents with T2DM/Obesity/
SD reported the poorest outcomes (vs. T2DM only): lower MCS (43.9 vs. 51.1), PCS 
(39.1 vs. 47.1), health utilities (0.62 vs. 0.73), greater absenteeism (5.5% vs. 2.0%), 
presenteeism (26.9% vs. 10.9%), overall work impairment (30.0% vs. 12.6%), activity 
impairment (43.5% vs. 21.9%), provider visits (7.7 vs. 4.6), and emergency room visits 
(0.29 vs. 0.16), all p< 0.05. CONCLUSIONS: Majority of respondents with T2DM and 
SD were obese, suggesting a strong link between obesity and SD. Coexistence of 
obesity and SD led to significantly negative impact on health status, productivity, 
and healthcare utilization in patients with T2DM. Interventions focusing on SD and 
obesity may be clinically and economically beneficial.
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OBJECTIVES: For patients with type 2 diabetes (T2DM), achieving optimal levels of 
hemoglobin A1c (HbA1c), blood pressure (BP), and LDL-cholesterol (LDL-C), or the 
“ABCs” of diabetes, has been linked to several health benefits, but goal attainment 
rates in the United States remain low. This study sought to determine how ABC goal 
attainment is associated with the presence of major depressive disorder (MDD) 
and Health-Related Quality of Life (HRQoL) among a national sample of patients 
with T2DM. METHODS: This study was a retrospective analysis of the National 
Health and Nutrition Examination Survey (NHANES) data from 2007-2012. Primary 
endpoints for ABC goal attainment were defined as HbA1c < 7%, BP < 130/80mmHg, 
and LDL-C < 100mg/dL. The study sample consisted of non-pregnant participants at 
least 20 years old with T2DM, stratified by presence of MDD. Comparisons between 
individuals who achieved and were unable to achieve simultaneous ABC goals were 
conducted using t-tests or chi-square analyses as appropriate. Multivariate logis-
tic regression was used to analyze which factors potentially influence ABC goal 
achievement. RESULTS: A total of 808 participants with T2DM met the inclusion 
criteria. The mean age for all participants was 60.5 years and 51.4% were female. 
Based on Patient Health Questionnaire (PHQ-9) scores, 11.63% of participants met 
the criteria for MDD. Overall, 23.7% of total participants were at goal for all 3 ABC 
parameters, with no significant difference in goal attainment between patients with 
or without MDD. Participants with T2DM and meeting criteria for MDD reported 
poorer general health, poorer physical health, and poorer mental health (p< 0.001 
for all) than those who did not meet criteria for MDD, according to results from the 
HRQoL survey. CONCLUSIONS: Among the study population with T2DM, presence 
of MDD showed no significant impact on ABC goal attainment. However, presence 
of MDD had a positive association with poor HRQoL.
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OBJECTIVES: Few indirect comparisons have been performed examining health-
related quality of life (HRQoL) data, owing in part to paucity of data collection. As 
health care delivery becomes increasingly patient-centered, examining HRQoL out-
comes with these methods will become important for decision making. This analysis 
utilized indirect comparison methods to assess differences in Impact of Weight on 
Quality of Life – Lite (IWQoL-Lite) total score for canagliflozin (CANA), compared 
to exenatide QW (ExQW), sitagliptin (SITA), and pioglitazone (PIO), using trial data 
evaluating these agents as add-on to metformin. METHODS: Published results 
from the DURATION-2 trial of ExQW compared to PIO and SITA, and subject-level 
data from a trial comparing CANA to SITA (DIA3006), were available for analyses. 
Disease characteristics and baseline IWQoL-Lite scores were similar, and both trials 
assessed change in IWQoL-Lite total score from baseline to Week 26. Bayesian fixed-
effect models with non-informative priors were used to estimate the difference in 
IWQoL-Lite total score for CANA (100 and 300 mg, pooled) versus ExQW, SITA, and 
PIO. Analyses were also performed to test the robustness of these results, including 
those that adjusted for potential determinants of HRQoL. RESULTS: In the unad-
justed analysis, the probability that CANA is better than ExQW, SITA, and PIO was 
60.0% (median difference [95% CrI]: –0.43 [–2.84, 3.62]), 89.9% (1.02 [–0.55, 2.58]), and 
99.5% (4.36 [1.06, 7.64]). Restricted to DURATION-2 inclusion and exclusion criteria, 
the probabilities were 61.6%, 82.1%, and 98.9%, respectively. Further adjustment 
for race and country differences yielded probabilities of 74.6% versus ExQW, 85.9% 
versus SITA, and 98.5% versus PIO. CONCLUSIONS: The adjusted analyses suggest 
that CANA is associated with at least similar IWQoL-Lite change scores compared 
to ExQW and greater improvements in IWQoL-Lite score compared to SITA and PIO. 
These analyses illustrate that indirect comparisons of HRQoL data should explore 
potential determinants of HRQoL.
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(48%), and energy/activity level (36%) for Physical; juvenalization (51%) and teasing/
bullying (33%) for Social; and self-confidence (45%) and worry (34%) for Emotional. 
Emotional and social impacts were often related to others’ perception or treat-
ment of the child as younger, and all impacts were moderated by physical growth. 
Additionally, children who began treatment later in life experienced more emotional 
and social impacts than children who started treatment at an earlier age. Children 
and caregivers reported consistent symptoms/impacts. Modifiers to the degree of 
impact of GHD were identified and include age at treatment, growth velocity, and 
having other children in family with GHD. Responses did not differ substantially 
among countries. CONCLUSIONS: Concept elicitation of the burden of disease for 
children with GHD identified key concepts that should be included in PRO/ObsRO 
measures to assess the impact of GHD and treatment.
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OBJECTIVES: To identify and compare the health outcomes profiles of adults receiv-
ing medical care at specialty clinics for symptomatic (chronic pain) and largely 
asymptomatic (diabetes) chronic conditions. METHODS: Patients receiving care at 
pain or diabetes clinic completed the PROMIS-29 instrument that measures 7 health 
domains. Item response theory-based scores are on the T-metric with a mean of 50 
and standard deviation (SD) of 10 based on the general United States population 
(norm). RESULTS: A total of 227 patients participated in the study (n= 128 chronic 
pain; n= 99 diabetes). The mean age was 46.7years (SD= 13.7), 56% were women, 
86.9% were non-Hispanic white, and 31.2% had < = 12 years of education. Pain clinic 
patients were significantly older and less educated than diabetes clinic patients, 
however there were no other demographic differences between patient groups. All 
7 domain scores were statistically significantly worse for the chronic pain clinic 
patients compared with diabetes clinic patients (P< 0.001 for all comparisons). 
The smallest and largest differences between clinics were observed for anxiety 
(mean difference= 11.4) and pain interference (mean difference= 22.0), respectively. 
Adjustment for age, sex, and education only slightly attenuated differences between 
the two patient populations. For example, the unadjusted mean difference between 
diagnostic groups for physical function was 17.7 (P< 0.001), while the mean differ-
ence was 16.02 (P< 0.001) when adjusted for demographic characteristics. The pain 
clinic sample had mean scores that were 0.9 to 1.7 SDs worse than the norm on all 
domains. CONCLUSIONS: Compared with patients with diabetes, chronic pain clinic 
patients had a substantially poorer PROMIS-29 health outcome profile. Findings indi-
cate that not only are health outcome profiles for chronic pain patients poor relative 
to the US population, but also poor relative to patients with a different chronic but 
relatively asymptomatic condition (diabetes) suggesting that aversive symptoms 
may have a more significant impact than chronic disease per se.
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OBJECTIVES: To measure the mental well-being experienced by patients with 
type 2 diabetes (T2D) by utilizing the SF-36v2 mental component summary 
(MCS). METHODS: Data were from the 2013 U.S. National Health and Wellness 
Survey. Respondents (aged ≥ 18 years) provided details about their health status 
and health care through self-administered, Internet-based questionnaires. The 
analytic sample included those self-reporting a T2D diagnosis. Mental well-being 
was defined by utilizing the SF-36v2 MCS. Based on the normed mean of 50 and 
standard deviation (SD) of 10 for the general population and the distribution of 
MCS scores within the analytic sample, categories were defined as good mental 
well-being (above the population mean; MCS ≥ 50), poor mental well-being (≤ 1 SD 
below the population mean; MCS ≥ 40 and < 50), and very poor mental well-being (> 1 
SD below the population mean; MCS< 40). RESULTS: The analytic sample consisted 
of 7852 respondents diagnosed with T2D. Of these, 22% (n= 1701) experienced very 
poor mental well-being, 23% (n= 1781) poor mental well-being, and 56% (n= 4370) 
good mental well-being. Very poor/poor mental well-being was associated with 
respondents who were younger, female, non-white, less educated, current smokers, 
and had lower household income (p< 0.001 for all). Respondents with very poor/poor 
mental well-being vs. good mental well-being had greater Charlson Comorbidity 
Index scores (mean of 1.99/1.77 vs. 1.59), and were more likely to be diagnosed with 
depression (57%/26% vs. 5%) or an anxiety disorder (44%/20% vs. 5%) (p< 0.001 for 
all). Poorer mental well-being also was associated with having T2D for a shorter 
period of time, use of insulin, experience with hypoglycemia, and greater likelihood 
of T2D related complications (p< 0.001 for all). CONCLUSIONS: Poorer mental well-
being, as measured by the SF-36v2 MCS, is associated with greater overall physical 
and psychiatric morbidity, as well as morbidity specifically associated with T2D.
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OBJECTIVES: Obesity is a strong risk factor for sleep disorders (SD) and type 2 dia-
betes mellitus (T2DM). SD and T2DM are often associated. This study examined the 
incremental burden of obesity and SD in patients with T2DM. METHODS: Data were 
analyzed from the 2012 US National Health and Wellness Survey, a nationally repre-
sentative, online survey of 71,157 adults (≥ 18 years). Respondents with T2DM were 
categorized into 4 groups: T2DM only; T2DM with obesity; T2DM with SD; T2DM with 
obesity and SD. Respondents provided information on health status (SF-36v2: men-
